Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2014
04/30/2014EP2723710A1 Fluorinated arylalkylaminocarboxamide derivatives
04/30/2014EP2723450A2 Combination therapy
04/30/2014EP2723449A2 Compounds for the treatment of cancers associated with human papillomavirus
04/30/2014EP2723439A1 Applicator system for applying a viscous liquid to the human skin
04/30/2014EP2723382A1 Methods and compositions for modulating voltage-gated calcium channel function
04/30/2014EP2723351A2 Compositions and methods for inhibition of expression of protein c (proc) genes
04/30/2014EP2723350A1 New uses of nanog inhibitors and related methods
04/30/2014EP2723349A2 Microrna-31 compositions and methods for use in autoimmune disease
04/30/2014EP2723348A2 Method for treating obesity
04/30/2014EP2723347A1 Prevention and treatment of inflammatory conditions
04/30/2014EP2723346A1 Compositions and methods useful for treating pediculosis
04/30/2014EP2723345A2 Composition comprising phosphatidylcholine as an active ingredient for attenuating toxicity of anticancer agent
04/30/2014EP2723344A1 Monoterpene-containing agent for combination therapy
04/30/2014EP2723343A2 Process of forming crystals for use in a personal care composition
04/30/2014EP2723342A1 Use of 10h-benzo[g]pteridine-2,4-dione derivatives
04/30/2014EP2723341A1 Fast dissolving azaperone granulate formulation
04/30/2014EP2723340A1 Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
04/30/2014EP2723339A2 Compounds for treating peripheral neuropathies and other neurodegenerative disorders
04/30/2014EP2723338A2 Selective inhibitors of histone deacetylase isoform 6 and methods thereof
04/30/2014EP2723337A1 Treatment of hepatitis c virus
04/30/2014EP2723336A1 Compositions for the treatment of fragile x syndrome
04/30/2014EP2723335A1 Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation
04/30/2014EP2723334A2 Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
04/30/2014EP2723333A1 Treatment and prevention of diseases related to oxidative stress
04/30/2014EP2723332A1 Novel compounds as diacylglycerol acyltransferase inhibitors
04/30/2014EP2723331A2 Non-leaching antimicrobial wound dressing
04/30/2014EP2723330A1 Vasoconstrictor-containing agent for combination therapy
04/30/2014EP2723329A1 Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist
04/30/2014EP2723328A1 Combination treatment comprising a hdac6 inhibitor and an akt inhibitor
04/30/2014EP2723326A1 Topical film-forming composition, and use thereof for treating mycoses
04/30/2014EP2723320A1 Liquid pharmaceutical composition comprising nitisinone
04/30/2014EP2723317A1 Phenylbutyrate in rectal form for the treatment of a motor neuron disease or a metabolic disease
04/30/2014EP2723197A1 Milk drink based on oyster mushroom lovastatin
04/30/2014EP2723196A1 Wheat germ extract obtained by protease hydrolysis and medical use thereof
04/30/2014EP2723195A1 Method for reducing the occurrence of infection in young children
04/30/2014DE102012021237A1 Substance as mixture of natural substances, useful for combating unicellular parasites in humans and animals, includes drug of natural origin from class of isoquinoline alkaloids, eugenol, and diterpenes of Cassan or non-Cassan type
04/30/2014CN203564510U Fumigating device for encephalopathy
04/30/2014CN103765212A Methods and compositions for treatment of cancer and autoimmune disease
04/30/2014CN103764847A Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer
04/30/2014CN103764830A Composition comprising inhibitors of IRS-1 and of VEGF
04/30/2014CN103764661A Novel pyrimidine derivative and pharmaceutical composition including same as an active ingredient
04/30/2014CN103764659A Glioblastoma inhibiting compounds and their use
04/30/2014CN103764658A Compounds, their pharmaceutical compositions and their uses as IDH1 mutants inhibitors for treating cancers
04/30/2014CN103764657A Hydroxymethylaryl-substituted pyrrolotriazines as ALKL inhibitors
04/30/2014CN103764656A Heterocyclyl aminoimidazopyridazines
04/30/2014CN103764654A Inhibitors of influenza viruses replication
04/30/2014CN103764653A Compounds and compositions as c-Kit kinase inhibitors
04/30/2014CN103764652A Tricyclic pyrazole sulfonamide compounds and methods of making and using same
04/30/2014CN103764651A 7-azaindole derivatives suitable for treatment of cancers
04/30/2014CN103764648A Pyrrolidine-3-ylacetic acid derivative
04/30/2014CN103764647A Metalloenzyme inhibitor compounds
04/30/2014CN103764646A Metalloenzyme inhibitor compounds
04/30/2014CN103764641A Partially saturated tricyclic compounds and methods of making and using same
04/30/2014CN103764640A ALDH-2 inhibitors in the treatment of addiction
04/30/2014CN103764637A Solid state forms of cabazitaxel and processes for preparation thereof
04/30/2014CN103764635A Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
04/30/2014CN103764633A 3,5-diamino-6-chloro-n-(n-(4-(4-(2-(hexyl (2,3,4,5,6-pentahydroxyhexyl) amino) ethoxy) phenyl) butyl) carbamimidoyl) pyrazine-2-carboxamide
04/30/2014CN103764631A Quinolone compound
04/30/2014CN103764630A Sweet flavor modifier
04/30/2014CN103764629A Positive allosteric modulators of nicotinic acetylcholine receptor
04/30/2014CN103764622A N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof
04/30/2014CN103764621A Epoxyeicosatrienoic acid analogs and methods of making and using the same
04/30/2014CN103764620A Novel ceramide analogues, processes for preparing same and uses thereof
04/30/2014CN103764619A Tetravalent platinum complex and pharmaceutical composition containing same
04/30/2014CN103764608A Indene derivatives for use in the treatment of inflammatory bowel disease
04/30/2014CN103764604A Stilbene analogs and methods of treating cancer
04/30/2014CN103764167A Oral compositions comprising an antacid, an anaesthetic and an inorganic matrix comprising silicon dioxide and titanium dioxide
04/30/2014CN103764161A Anti-cancer composition comprising Wnt decoy receptors
04/30/2014CN103764153A Poly(acrylate) polymers for in vivo nucleic acid delivery
04/30/2014CN103764152A Anti-tumor agent
04/30/2014CN103764151A Antagonists of CB1 receptor
04/30/2014CN103764150A Alcaftadine for use in treatment of urticaria
04/30/2014CN103764149A Novel ticagrelor co-crystal
04/30/2014CN103764148A Voltage-gated sodium channel blockers
04/30/2014CN103764147A Pyruvate kinase activators for use in therapy
04/30/2014CN103764146A Nicorandil-containing pharmaceutical composition
04/30/2014CN103764145A Isoxazolines as therapeutic agents
04/30/2014CN103764144A Synergistic combinations of pi3k- and mek-inhibitors
04/30/2014CN103764143A Lipoxygenase inhibitors
04/30/2014CN103764142A Use of 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methylpropyl]amino-3,4-dihydro- 2h-1,5-benzoxathiepine for treating cancer and in particular for preventing and/or treating cancer metastases
04/30/2014CN103764141A Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
04/30/2014CN103764140A Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases
04/30/2014CN103764139A Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset
04/30/2014CN103764138A Taxane and abeo-taxane analogs
04/30/2014CN103764137A Eosinophil peroxidase compositions and methods of their use
04/30/2014CN103764136A Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
04/30/2014CN103764135A Transdermal therapeutic system for 5-aminolevulinic acid hydrochloride
04/30/2014CN103764134A Use of organic compound for the treatment of noonan syndrome
04/30/2014CN103764133A Clenbuterol for use in treatment of autism
04/30/2014CN103764132A Oral formulations of mitochondrially-targeted antioxidants and their preparation and use
04/30/2014CN103764131A Fish anesthetic and method
04/30/2014CN103764130A Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone
04/30/2014CN103764126A Pharmaceutical composition and solid galenic form having a high dronedarone content, and method for preparing same
04/30/2014CN103764125A Multi-layered release formulation
04/30/2014CN103764122A Liposome comprising at least one cholesterol derivative
04/30/2014CN103764119A Intranasal pharmaceutical dosage forms comprising naloxone
04/30/2014CN103764118A Topical ophthalmological pharmaceutical composition containing sorafenib
04/30/2014CN103763942A Epicatechin for alleviating symptoms of allergy
04/30/2014CN103763941A Metabolic imprinting effects of specifically designed lipid component
04/30/2014CN103763940A Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
1 ... 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 ... 7860